Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has provided an update.
China Resources Pharmaceutical Group has reported the unaudited first-quarter 2026 financial performance of its 63.22%-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical. CR Sanjiu posted revenue of RMB 8.13 billion, up from RMB 6.85 billion a year earlier, while net profit eased to RMB 1.21 billion from RMB 1.33 billion.
The subsidiary recorded a sharp swing in cash flow, with a net decrease in cash and cash equivalents of RMB 1.32 billion versus an increase of RMB 1.25 billion in the prior-year quarter, and cash balances fell to RMB 3.20 billion. Despite this, CR Sanjiu’s owner’s equity rose to RMB 39.68 billion as total liabilities declined, indicating a stronger balance sheet, though management cautioned that the unaudited figures may be adjusted and do not fully reflect the parent group’s overall financial position.
More about China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical conglomerate focused on medical and pharmaceutical products, with operations spanning manufacturing and distribution in mainland China. Its key subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., is listed on the Shenzhen Stock Exchange and contributes significantly to the group’s revenue and earnings profile.
Average Trading Volume: 18,740,562
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$36.69B
See more data about 3320 stock on TipRanks’ Stock Analysis page.